Compare Regeneron Pharmaceuticals Inc (REGN) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wynn Resorts, Limited — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Wynn Resorts, Limited trades at $94.25 (market cap $9.82B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.2× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays the higher dividend (1.06%). Which is the better fit depends on your goals.
| REGN | WYNN | |
|---|---|---|
Market Cap | $70.79B | $9.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $812.27 | $133.34 |
52-Week Low | $545.46 | $94.63 |
Enterprise Value | $64.74B | $20.19B |
Dividend Yield | 0.56% | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
